Vidaza powder for suspension for injection; azacitidine for injection

Celgene Corporation

Revision date : 2017-04-03

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
GHS08 GHS07 GHS09
Health risk rating 5
Safety risk rating 1
Environmental risk rating 5

General Information

Version

3.0.0

Revision date

2017-04-03

Product name

Vidaza powder for suspension for injection; azacitidine for injection

Product Synonyms

Mylosar, Ladakamycin

Chemical name

Mixture - contains pyrimidine nucleoside analog

CAS No.

320-67-2

1.2.1 Relevant identified uses

Bulk formulated pharmaceutical product/ Formulated pharmaceutical product of the substance or packaged in final form for patient use; indicated for the treatment of certain mixture and uses myelodysplastic syndromes

Emergency telephone

+1 (800) 424-9300, +1 (703) 527-3887

Icons in SDS

GHS07 GHS08 GHS09

Company Information

company name

Celgene Corporation

e-mail address of the competent person responsible for the Safety Data Sheet

MSDScoordinator@Celgene.com

GHS Information

Signal word

Danger

Hazard Codes

Hazard statements (CLP)

H302, H341, H350, H360FD, H372, H400, H410

Hazard statements

Code

Statements

H302

Harmful if swallowed

H341

Suspected of causing genetic defects

H350

May cause cancer

H360FD

May damage fertility. May damage the unborn child.

H372

Causes damage to organs through prolonged or repeated exposure

H400

Very toxic to aquatic life

H410

Very toxic to aquatic life with long lasting effects

Section 2

SECTION 2: Hazards identification

WHMIS 2015 Classification of the substance or mixture Drugs in the finished state and intended for the final user are not subject to labeling in the US, EU or Canada. Please consult the prescribing/packaging information. The classification and labelling listed below is for bulk Vidaza Globally Harmonized System [GHS] Carcinogenic - Category 1B. Germ Cell Mutagenicity - Category 2. Reproductive Toxicity - Category 1B. Acute toxicity - oral - Category 4. Specific Target Organ Toxicity (repeated exposure) - Category 1. Aquatic toxicity (acute) - Category 1 Aquatic toxicity (chronic) - Category 1 HAZARDS IDENTIFICATION …continued

Signal word

Danger

Hazard statements

H302 - Harmful if swallowed. H341 - Suspected of causing genetic defects. H350 - May cause cancer. H360FD - May damage fertility. May damage the unborn child. H372 - Causes damage to hematological and gastrointestinal systems through prolonged or repeated exposure. H400 - Very toxic to aquatic life. H410 - Very toxic to aquatic life with long-lasting effects. precautions have been read and understood. P260 - Do not breathe dust. P264 - Wash hands thoroughly after handling. P270 - Do not eat, drink or smoke when using this product. P273 - Avoid release to the environment. P281 - Use personal protective equipment as required. P308 + P313 - If exposed or concerned: get medical advice/attention. P301+P312 IF SWALLOWED Call a Poison Center or doctor/physician if you feel unwell. P330 - Rinse mouth. P391 - Collect spillage. P405 - Store locked up. P501 - Dispose of contents/container to location in accordance with local/regional/national/international regulations. P280 - Wear protective gloves/eye protection/face protection. P308 + P313 - IF exposed or concerned: get medical advice/attention.

Precautionary statements

P201 - Obtain special instructions before use. P202 - Do not handle until all safety

2.3 Other hazards

The most commonly occurring adverse effects with therapeutic use include hematological toxicity (e.g., thrombocytopenia, anemia, neutropenia), fever, gastrointestinal effects (e.g., nausea, vomiting, diarrhea, constipation), fatigue, injection site erythema, ecchymosis (skin discoloration caused by escape of blood into tissues from ruptured blood vessels). Other effects may include hypotension, shortness of breath, liver/kidney toxicity and electrolyte abnormalities. Post- marketing reports of interstitial lung disease and tumor lysis syndrome may also be azacitidine-related. Note This mixture is classified as hazardous under GHS as implemented by Regulation

2.1 Classification of the substance or mixture

Drugs in the finished state and intended for the final user are not subject to substance or mixture

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.